Last reviewed · How we verify
mannitol 20% intravenous fluid
Mannitol is an osmotic diuretic that draws fluid from tissues into the intravascular space and increases urine output to reduce intracranial and intraocular pressure.
Mannitol is an osmotic diuretic that draws fluid from tissues into the intravascular space and increases urine output to reduce intracranial and intraocular pressure. Used for Cerebral edema and elevated intracranial pressure, Acute glaucoma and elevated intraocular pressure, Oliguria and acute kidney injury prevention.
At a glance
| Generic name | mannitol 20% intravenous fluid |
|---|---|
| Also known as | mannitol 20% (Manufactured by Allmed Middle East, Egypt). |
| Sponsor | Ain Shams University |
| Drug class | Osmotic diuretic |
| Modality | Small molecule |
| Therapeutic area | Neurology, Ophthalmology, Critical Care |
| Phase | FDA-approved |
Mechanism of action
Mannitol is a sugar alcohol that creates an osmotic gradient, pulling water from the extravascular and intracellular compartments into the blood vessels and then into the urine. This reduces brain edema and intracranial pressure by decreasing total body water content. It is filtered by the glomerulus but poorly reabsorbed by renal tubules, promoting diuresis and further fluid removal.
Approved indications
- Cerebral edema and elevated intracranial pressure
- Acute glaucoma and elevated intraocular pressure
- Oliguria and acute kidney injury prevention
Common side effects
- Dehydration and hypovolemia
- Hypernatremia and electrolyte imbalance
- Rebound intracranial pressure elevation
- Headache
- Nausea and vomiting
- Thrombophlebitis at injection site
Key clinical trials
- Safety of Short Hydration Method for Cisplatin Administration Compared With Conventional Hydration (NA)
- Comparative Study Between Hydrocortisone and Mannitol in Treatment of Postdural Puncture Headache (PHASE4)
- Study of Stroke Related Edema Treatments (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mannitol 20% intravenous fluid CI brief — competitive landscape report
- mannitol 20% intravenous fluid updates RSS · CI watch RSS
- Ain Shams University portfolio CI